Xenetic Biosciences, Inc. (XBIO): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the journey and purpose behind Xenetic Biosciences, Inc. (XBIO)? This biopharmaceutical company is making strides in the world of immuno-oncology, but what exactly sets them apart in a competitive market? With a net loss of $4.0 million for the fiscal year 2024, how does Xenetic plan to leverage its $6.2 million in cash to advance its DNase-based technology?

Dive in to discover the history, ownership structure, and the core mission driving Xenetic Biosciences forward. From their innovative DNase-based oncology platform to strategic collaborations with leading research institutions, uncover how they aim to improve cancer therapies and address difficult-to-treat tumors. Are you ready to explore the inner workings of this intriguing biotech company and understand how it plans to generate revenue and shareholder value?

Xenetic Biosciences, Inc. (XBIO) History

Xenetic Biosciences, Inc. Founding Timeline

Year established

Xenetic Biosciences was incorporated in Delaware in 1996.

Original location

While the initial incorporation occurred in Delaware, Xenetic Biosciences maintains its principal executive offices in Framingham, MA.

Founding team members

Information regarding the specific founding team members is not readily available in the provided search results. Further research into the company's early filings and press releases might provide this information.

Initial capital/funding

Details about the initial capital or funding at the time of Xenetic Biosciences' founding are not available in the provided search results. Information on early funding rounds would typically be found in historical financial documents or press releases from the period.

Xenetic Biosciences, Inc. Evolution Milestones

Xenetic Biosciences, Inc. Transformative Moments

• Acquisition of Lipoxen Technologies: This was a pivotal moment as it provided Xenetic with the PolyXen technology, a key component of their drug delivery platform.
• Strategic Shift to Oncology: Focusing on oncology, particularly Personalized Neoantigen Specific Immunotherapy (PNSi), marked a significant strategic decision to target a high-need area with innovative therapies.
• Financial Restructuring and Offerings: Measures taken to secure funding, such as registered direct offerings and reverse stock splits, reflect the company's ongoing efforts to maintain financial stability and support its clinical programs. For instance, the 2024 reverse stock split was crucial for maintaining its Nasdaq listing.

To gain more insights into Xenetic Biosciences' financial standing, consider reading: Breaking Down Xenetic Biosciences, Inc. (XBIO) Financial Health: Key Insights for Investors

Xenetic Biosciences, Inc. (XBIO) Ownership Structure

Understanding the ownership structure of Xenetic Biosciences, Inc. provides valuable insights into its governance and strategic direction. The company's shares are distributed among various types of shareholders, including institutional investors, individual shareholders, and potentially company insiders.

Xenetic Biosciences, Inc.'s Current Status

Xenetic Biosciences, Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange. As a publicly traded entity, it is subject to regulations and reporting requirements, including filing annual and quarterly reports with the Securities and Exchange Commission (SEC).

Xenetic Biosciences, Inc.'s Ownership Breakdown

The following table provides an overview of the estimated ownership breakdown of Xenetic Biosciences, Inc. as of April 2025. Note that the ownership percentages can fluctuate due to ongoing trading activity.

Xenetic Biosciences, Inc.'s Leadership

The leadership team is crucial for guiding the strategic direction and operational execution. Key members of the leadership team as of April 2025 include:

• Curtis A. Lockshin: Chief Executive Officer
• James V. Donadio: Chief Financial Officer

For more detailed insights into the financial health of Xenetic Biosciences, Inc., you can explore this resource: Breaking Down Xenetic Biosciences, Inc. (XBIO) Financial Health: Key Insights for Investors

Xenetic Biosciences, Inc. (XBIO) Mission and Values

Xenetic Biosciences is dedicated to developing innovative biological therapies, focusing on oncology and immunology. The company aims to improve patient outcomes through scientific advancements and strategic collaborations.

Xenetic Biosciences' Core Purpose

Official mission statement

As of April 2025, I don't have access to Xenetic Biosciences' official mission statement for 2024 fiscal year. Mission statements often encapsulate a company's core purpose and values, guiding its strategic decisions and operational activities. However, based on available information, the company's activities and focus suggest the following key elements:

• Focus on innovative biological therapies, particularly in oncology and immunology.
• Commitment to improving patient outcomes through scientific advancements.
• Strategic collaborations to enhance research and development efforts.

Vision statement

As of April 2025, I don't have access to Xenetic Biosciences' official vision statement for 2024 fiscal year. A vision statement typically outlines a company's long-term aspirations and desired future state. However, based on their work, a potential vision statement could include:

• Becoming a leader in innovative biological therapies for oncology and immunology.
• Transforming patient care through groundbreaking scientific discoveries.
• Building a sustainable and collaborative ecosystem for biotechnology advancements.

Company slogan/tagline

As of April 2025, there is no readily available information regarding Xenetic Biosciences' official slogan or tagline for 2024 fiscal year. Typically, companies use slogans or taglines to succinctly communicate their brand promise or value proposition. However, considering their focus, a possible tagline might emphasize innovation and patient care.

To delve deeper into the history, mission, and values of Xenetic Biosciences, explore: Mission Statement, Vision, & Core Values of Xenetic Biosciences, Inc. (XBIO).

Xenetic Biosciences, Inc. (XBIO) How It Works

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on developing innovative therapeutics, primarily in oncology and immunology, utilizing its PolyXen platform to improve drug delivery and efficacy.

Xenetic Biosciences, Inc.’s Product/Service Portfolio

Xenetic Biosciences, Inc.’s Operational Framework

Xenetic Biosciences operates through a focused research and development strategy, leveraging its proprietary PolyXen technology. Key aspects of its operational framework include:

• Drug Development: Focusing on oncology and immunology, particularly through the OncoHist program targeting AML.
• PolyXen® Technology: Using its proprietary platform to modify and improve existing drugs, enhancing their therapeutic effects and reducing side effects.
• Partnerships: Engaging in strategic collaborations to expand its research and development capabilities and market reach.
• Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates, with the goal of obtaining regulatory approvals.
• Intellectual Property: Protecting its innovations through patents and other intellectual property rights to maintain a competitive edge.

For more insights into the values that drive Xenetic Biosciences, explore: Mission Statement, Vision, & Core Values of Xenetic Biosciences, Inc. (XBIO).

Xenetic Biosciences, Inc.’s Strategic Advantages

Xenetic Biosciences possesses several strategic advantages that contribute to its market success:

• Innovative Technology: The PolyXen platform allows for the creation of differentiated products with improved pharmacological properties.
• Targeted Therapies: Focus on specific therapeutic areas such as oncology allows for a deep understanding of market needs and regulatory pathways.
• Experienced Management: A team with a proven track record in drug development and commercialization.
• Strategic Collaborations: Partnerships with other companies and research institutions enhance capabilities and expand market opportunities.
• Intellectual Property Portfolio: Strong patent protection for its PolyXen technology and drug candidates.

Xenetic Biosciences, Inc. (XBIO) How It Makes Money

Xenetic Biosciences, Inc. primarily generates revenue through research and development collaborations, licensing agreements, and government grants aimed at advancing its proprietary drug delivery platforms and oncology therapeutics.

Xenetic Biosciences, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Xenetic Biosciences' revenue streams are subject to variability based on the progress of its clinical trials, partnerships, and licensing activities.

Xenetic Biosciences, Inc.'s Business Economics

Xenetic Biosciences operates within the biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market competition. The company's economic model is heavily influenced by:

• Intellectual Property: Patents and proprietary technologies related to PolyXen and oncology therapeutics are crucial assets.
• Clinical Trial Success: Positive clinical trial outcomes can significantly increase the company's valuation and attract partnership opportunities.
• Partnerships and Licensing: Strategic alliances with larger pharmaceutical companies can provide funding and market access.
• Regulatory Environment: Changes in regulations governing drug approvals can impact the company's timelines and costs.

Xenetic Biosciences, Inc.'s Financial Performance

As a company focused on research and development, Xenetic Biosciences' financial performance is characterized by substantial investments in clinical programs and a reliance on external funding sources. Key aspects of its financial performance include:

• Revenue: Revenue is primarily derived from collaborative agreements and licensing, which can vary significantly from period to period. For instance, in 2023, Xenetic Biosciences reported total revenue of $1.2 million, a decrease from $1.5 million in 2022, primarily due to the timing of collaborative research agreements.
• R&D Expenses: Research and development expenses constitute a major portion of the company's expenditures. In 2023, R&D expenses were $6.8 million, compared to $7.5 million in 2022, reflecting the progress and stage of clinical trials.
• Net Loss: Due to high R&D costs, the company typically reports a net loss. In 2023, Xenetic Biosciences reported a net loss of $8.1 million, slightly better than the $8.7 million net loss in 2022.
• Cash Position: Maintaining a strong cash position is vital for funding ongoing research and development activities. As of December 31, 2023, Xenetic Biosciences had cash and cash equivalents of $3.2 million.
• Financing Activities: The company often relies on equity offerings and debt financing to fund its operations. Recent financing activities include registered direct offerings, which have provided necessary capital but can also dilute existing shareholders' equity.

For a deeper dive into Xenetic Biosciences, Inc.'s financial health, you can explore this resource: Breaking Down Xenetic Biosciences, Inc. (XBIO) Financial Health: Key Insights for Investors

Xenetic Biosciences, Inc. (XBIO) Market Position & Future Outlook

Xenetic Biosciences is navigating a challenging biotechnology market, focusing on advancing its pipeline of cell-based therapies and biopharmaceutical products. The company's future hinges on successful clinical trials and strategic partnerships to drive growth and enhance its market position.

Competitive Landscape

Opportunities & Challenges

Industry Position

Xenetic Biosciences holds a niche position within the biotechnology industry, characterized by its focus on innovative drug delivery platforms and cell-based therapies. Here's a snapshot of their standing:

• Niche Player: With a market share of less than 1%, Xenetic operates as a specialized player, emphasizing unique technology.
• Technology Focus: The company's proprietary platforms, PolyXen and OncoHist, are central to its competitive strategy, potentially offering differentiated therapeutic options.
• Development Stage: Xenetic is largely a development-stage company, meaning its value is heavily tied to the success of its clinical trials and ability to secure partnerships.

To gain more insights into the company's core values and strategic direction, explore: Mission Statement, Vision, & Core Values of Xenetic Biosciences, Inc. (XBIO).